Trial Profile
A Phase 2, single-masked, multicentre study to evaluate the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular oedema (DME)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs THR 317 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors Oxurion; ThromboGenics
- 06 Jun 2019 according to an Oxurion media release, data from the study were presented at the biannual Retina Meeting (FLORetina 2019).
- 06 Jun 2019 Results presented in an Oxurion media release.
- 19 Jul 2018 According to a ThromboGenics media release, results will be presented in an upcoming ophthalmology meeting.